Sukhi Jagpal
Keine laufenden Positionen mehr
Karriereverlauf von Sukhi Jagpal
Ehemalige bekannte Positionen von Sukhi Jagpal
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
SIERRA ONCOLOGY, INC. | Finanzdirektor/CFO | 01.02.2015 | 01.07.2022 |
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | Comptroller/Controller/Auditor | 01.03.2003 | 06.03.2013 |
Finanzdirektor/CFO | 10.07.2012 | 26.01.2015 |
Ausbildung von Sukhi Jagpal
Queen's University | Masters Business Admin |
Johnson Graduate School of Management | Masters Business Admin |
Statistik
International
Kanada | 3 |
Vereinigte Staaten | 3 |
Operativ
Masters Business Admin | 2 |
Director of Finance/CFO | 2 |
Comptroller/Controller/Auditor | 1 |
Sektoral
Consumer Services | 3 |
Commercial Services | 2 |
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
QLT, Inc.
QLT, Inc. Miscellaneous Commercial ServicesCommercial Services QLT, Inc. is a biotechnology company, which engages in the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. It also focuses on developing synthetic retinoid program for the treatment of certain inherited retinal diseases. The company was founded by Julia G. Levy and John C. Brown on February 3, 1981 and is headquartered in Vancouver, Canada. | Commercial Services |
Sierra Oncology, Inc.
Sierra Oncology, Inc. BiotechnologyHealth Technology Sierra Oncology, Inc. was a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focused on advanced targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded in May 2003 and is headquartered in San Mateo, CA. | Health Technology |
- Börse
- Insiders
- Sukhi Jagpal
- Erfahrung